Darbepoetin for Anemia of Cancer

In an international study, researchers failed to demonstrate a significant benefit for ESAs in patients with AoC who were not receiving myelosuppressive chemotherapy or radiotherapy.

Erythropoiesis-stimulating agents (ESAs) have been used extensively to treat and prevent anemia of cancer (AoC). Unfortunately, results of recent trials have raised concerns about risks that might be associated with these agents, particularly for off-label uses, such as AoC that is not associated with active chemotherapy. In a multinational study, investigators assessed whether darbepoetin alfa (DA; Aranesp) was safe and effective for treatment of AoC in patients who were not receiving active treatment.

Eligible patients had active cancer for which no further chemotherapy or radiotherapy was planned and were anemic (hemoglobin [Hb] ≤11 g/dL). All 985 participants had Eastern Cooperative Oncology Group performance scores ≥2, life expectancy ≥…

Reviewing Author

Barbara A. Murphy, MD